John Crowley, CEO of the Biotechnology Innovation Organization (Credit: BIO via website)
June 11, 2024 09:02 AM EDT
China
In Focus

BIO's new CEO takes a pa­tri­ot­ic piv­ot to win back Con­gress, push­ing in­dus­try to re­think Chi­na re­la­tion­ship

Andrew Dunn

Senior Biopharma Correspondent

Jared Whitlock

Features Editor

Max Bayer

Pharma Reporter

SAN DIEGO — Fac­ing an ex­is­ten­tial mo­ment in how drugs are de­vel­oped and sold, biotech’s key lob­by­ing group has en­trust­ed a new leader, who is wrap­ping …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Lay­offs at Gink­go and Xel­lia; Melo­dia and Alivex­is ink $275M part­ner­ship

The End­points Slack in­ter­view: Saji Wick­ra­masekara on where AI miss­es the mark — and what's next for Bench­ling

Sci­en­tists just dis­cov­ered a new ge­net­ic clue for de­lay­ing Alzheimer’s dis­ease. It’s al­ready in­spir­ing drug ...

Mon­cef Slaoui joins board at mR­NA biotech; Gami­da Cell re­tools with ex-Am­ryt CEO at the helm

FDA widens Sarep­ta’s Duchenne gene ther­a­py la­bel to old­er boys in sig­nif­i­cant ex­pan­sion of use

Tec­ton­ic en­ters pub­lic mar­kets in one of few biotech re­verse merg­ers this year

A service from the Financial Times